ClinicalTrials.gg
RecruitingNCT05548712Updated Dec 20, 2023

The Effect of PEMF for Patients With Knee OA

An interventional study of Pulse Electromagnetic Field and Sham Pulse Electromagnetic Field in Knee Osteoarthritis and Knee Pain Chronic, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled May 2022, registered Aug 2022).
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong — 9 open to participants now, 10 under way, none of them phase 3. Osteoarthritis, Knee · Chinese University of Hong Kong.

Planned enrollment
5th of 16
80 · median 64
Started
2022
with 4 others
No phase
15 of 20
8 open now
Registered
10th of 20
by date

Among the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2022, is one of 15 with no phase, and was the 10th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

9 of the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Health care costs are increasing alarmingly, which will impose an overwhelming economic burden to an aging society like that of Hong Kong. For example, degenerative musculoskeletal disorders such as osteoarthritis (OA) present a grand challenge with its high prevalence (>40% in the elderly suffered from knee OA). OA is a debilitating progressive disease with typical symptoms such as acute pain causing loss of mobility Currently there is no cure for OA. Pharmacological treatment and new regenerative technologies such as stem cell therapy are actively being developed, but most of these options are very expensive per se, and side effects are not uncommon. Costeffectiveness is also a major consideration for devising new therapeutic modalities for OA.

There are emerging evidences showing that pulsed electromagnetic field (PEMF) can modulae mitochondrial activities for muscle gain. PEMF exposure on top of regular exercise training may promote muscle regeneration and tissue healing.

This study aims to conduct a double-blinded, randomized controlled trial to investigate the effect of PEMF treatment on knee pain in patients with knee OA. We hypothesize that PEMF treatment is effective to relief in pain and improve knee function in Knee OA subjects.

Based on the aim of this study, older adult patients (aged 50 or above) with knee OA with Kellgren-Lawrence grade 2-4 by X-ray, have sedentary lifestyle (Tegner activity level less or equal to 3), no acute knee injuries in past 12 months, no muscle strain in past 12 months and not degenerative joint disease in other joints except the involved knee.

To estimate the improvement of patients, isometric quadricep muscle strength, posture assessment, serum myokine level, serum vitamin D level and selfreported outcome with questionnaires will be performed.

03

Conditions studied

  • Knee Osteoarthritis
  • Knee Pain Chronic

Keywords

  • Pulse electromagnetic field
  • PEMF
  • Knee Osteoarthritis
  • Knee OA
  • Knee pain
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 50 or above
  2. knee OA with Kellgren-Lawrence grade 2-4 by X-ray
  3. Sedentary lifestyle (Tegner activity level ≤ 3)
  4. No acute knee injuries in past 12 months
  5. No muscle strain in past 12 months
  6. No degenerative joint diseases in other joints except the involved knee

Exclusion criteria

Exclusion Criteria:

  1. Age smaller than 50 years old
  2. Experienced any concomitant bone fracture, ACL injury, major meniscus injury
  3. Any rheumatological diseases
  4. Metal implants that would cause interference on MRI
  5. Previous contralateral knee injury
  6. Recent knee injections (prior 3 months)
  7. Physical inability to undertake testing procedures
  8. Pregnancy or possibility of pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Device: Pulse Electromagnetic Field

  • Sham comparator
    Sham group

    Device: Sham Pulse Electromagnetic Field

Interventions

  • DevicePulse Electromagnetic Field

    Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.

  • DeviceSham Pulse Electromagnetic Field

    Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change of Peak torque of Isometric muscle strength

    The peak torque in kgf will be recorded with in 2 trials in the 5 seconds isometric muscle strength test.

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

Secondary outcomes

  1. International Physical Activity Questionnaire

    Consists of four items recording the subject's time of spending on physical activities during the past 7 days with a validated Chinese version of the quantitative physical activity questionnaire, and the physical activity level will be evaluated by Metabolic Equivalent of task(MET) per minute and classified as physical level with Low, Moderate or High.

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  2. Tegner activity score

    This is an activity level scaled from 1 (low activity) to 10 (high activity).

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  3. Short Form-36 questionnaires (SF-36)

    This is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  4. Serum myokine evaluation

    Phlebotomy (5ml) will be performed on the day before PEMF treatment, at 4- and 8- weeks after commencement of treatment, and at 8 months after the commencement of intervention. The serum will be prepared by centrifugation and kept in a -80o freezer until use. Quantitative analysis for myokines and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml. These include Brain-derived neurotrophic factor (BDNF), Fibroblast growth factor-21 (FGF-21), Interleukin-6 (IL-6), IL-15, Irisin, Myostatin (MSTN)/GDF8, Insulin-like growth factor 1 (IGF-1), FGF-2, IL-8, Follistatin, Musclin, Myonectin, Decorin, Meteorinlike, Osteopontin, Secreted protein acidic and rich in cysteine (SPARC), Klotho, Procollagen type III Nterminal peptide (P3NP), and C- terminal of troponin T1 (TNNT1).

    Time frame: pre PEMF treatment, 3-months, 6-months, and 12-months after the commencement of PEMF

  5. The speed and rate of force development in 6 repetitions in chair stand test

    The rate of force development will be determined as the mean slope of the rising force of the first force peak of each of the 2nd to the 6th repetition in the interval of 30-70% exerted peak force. Results are reported as the mean of the two fastest approved trials in body weight per second (BW/s).

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  6. Change of centre of pressure with the position of double leg squat

    The centre of pressure excursion range in the anterior-posterior direction in mm will be recored.

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  7. Change of centre of pressure with the position of static postural codition

    The centre of pressure excursion range in the anterior-posterior direction in mm will be recored.

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  8. Change of centre of pressure with the position of dynamic postural codition

    The centre of pressure excursion range in the anterior-posterior direction in mm will be recored.

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  9. Serum vitamin D level and vitamin D metabolites evaluation

    Blood samples will be taken under non-fasting conditions. Serum / plasma obtained will be immediately stored at -80°C until analysis. Serum 25(OH) Vit-D assay: Serum 25(OH)Vit-D levels will be measured by commercial 25(OH) Vitamin D ELISA kit (Abcam ab213966) according to the manufacturer's instruction, providing the quantitative determination of 25(OH) Vitamin D3 and 25(OH) Vitamin D2. Sensitivity: 1.98 ng/ml (Range: 0.5 ng/ml - 1010 ng/ml).

    Time frame: pre PEMF treatment, 3-months, 6-months, and 12-months after the commencement of PEMF

  10. Visual Analogue Scale

    The subjective measurement for chronic and acute pain will be recorded by the Visual Analogue Scale (VAS). VAS consists of a 10-cm line which represents the continuum between "painless" and "worst pain from 0 cm to 10 cm. The subject will be asked to draw a mark of it before and after each PEMF treatment session.

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

  11. Change of the scoring of Knee injury and Osteoarthritis Outcome Score

    Consist of 42 items with 5 subscapes: pain, other symptoms, function in daily living (ADL), function in sport and recreation (Sport/Rec), and knee-related quality of life (QOL) from 0% to 100% where higher score indicate a better outcome in each subscape.

    Time frame: pre PEMF treatment , 2-months, 3-months, 6-months, and 12-months after the commencement of PEMF

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: starting 6 months after publication

Access criteria: Journal reviewers

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Sep 2024, 28 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 28 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2022
First posted
Sep 21, 2022
StartActual
May 5, 2022
Primary completionEst.
Sep 15, 2024
CompletionEst.
Sep 15, 2024
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05548712
Responsible party
Prof. Tim-Yun Michael ONG (Clinical Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Sep 21, 2022
Start date
May 5, 2022
Primary completion
Sep 15, 2024 (estimated)
Completion
Sep 15, 2024 (estimated)
Last update
Dec 20, 2023

Study contacts

Michael Tim-Yun Ong
Contact
michael.ong@cuhk.edu.hk
26364171
Michael Tim-Yun Ong
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion